Sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience

被引:21
作者
Briere, Tina Marie [1 ]
McAleer, Mary Frances [2 ]
Levy, Lawrence B. [2 ]
Yang, James N. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, 1400 Pressler St,Unit 1420, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
来源
RADIATION ONCOLOGY | 2017年 / 12卷
关键词
VMAT; IMRT; Glioblastoma multiforme; Radiation therapy; INTENSITY-MODULATED RADIOTHERAPY; HIGH-GRADE GLIOMAS; NEWLY-DIAGNOSED GLIOBLASTOMA; ADJUVANT TEMOZOLOMIDE; BRAIN METASTASES; MULTIFORME; DELINEATION; CONCOMITANT; PATTERNS; TRIAL;
D O I
10.1186/s13014-017-0810-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Patients with glioblastoma multiforme (GBM) require radiotherapy as part of definitive management. Our institution has adopted the use of volumetric arc therapy (VMAT) due to superior sparing of the adjacent organs at risk (OARs) compared to intensity modulated radiation therapy (IMRT). Here we report our clinical experience by analyzing target coverage and sparing of OARs for 90 clinical treatment plans. Methods: VMAT and IMRT patient cohorts comprising 45 patients each were included in this study. For all patients, the planning target volume (PTV) received 50 Gy in 30 fractions, and the simultaneous integrated boost PTV received 60 Gy. The characteristics of the two patient cohorts were examined for similarity. The doses to target volumes and OARs, including brain, brainstem, hippocampi, optic nerves, eyes, and cochleae were then compared using statistical analysis. Target coverage and normal tissue sparing for six patients with both clinical IMRT and VMAT plans were analyzed. Results: PTV coverage of at least 95% was achieved for all plans, and the median mean dose to the boost PTV differed by only 0.1 Gy between the IMRT and VMAT plans. Superior sparing of the brainstem was found with VMAT, with a median difference in mean dose being 9.4 Gy. The ipsilateral cochlear mean dose was lower by 19.7 Gy, and the contralateral cochlea was lower by 9.5 Gy. The total treatment time was reduced by 5 min. The difference in the ipsilateral hippocampal D-100% was 12 Gy, though this is not statistically significant (P = 0.03). Conclusions: VMAT for GBM patients can provide similar target coverage, superior sparing of the brainstem and cochleae, and be delivered in a shorter period of time compared with IMRT. The shorter treatment time may improve clinical efficiency and the quality of the treatment experience. Based on institutional clinical experience, use of VMAT for the treatment of GBMs appears to offer no inferiority in comparison to IMRT and may offer distinct advantages, especially for patients who may require re-irradiation.
引用
收藏
页数:9
相关论文
共 37 条
  • [1] Intensity-modulated radiation therapy in newly diagnosed glioblastoma: A systematic review on clinical and technical issues
    Amelio, Dante
    Lorentini, Stefano
    Schwarz, Marco
    Amichetti, Maurizio
    [J]. RADIOTHERAPY AND ONCOLOGY, 2010, 97 (03) : 361 - 369
  • [2] REGROWTH PATTERNS OF GLIOBLASTOMA-MULTIFORME RELATED TO PLANNING OF INTERSTITIAL BRACHYTHERAPY RADIATION-FIELDS
    BASHIR, R
    HOCHBERG, F
    OOT, R
    [J]. NEUROSURGERY, 1988, 23 (01) : 27 - 30
  • [3] RADIATION THERAPY AND HEARING LOSS
    Bhandare, Niranjan
    Jackson, Andrew
    Eisbruch, Avraham
    Pan, Charlie C.
    Flickinger, John C.
    Antonelli, Patrick
    Mendenhall, William M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (03): : S50 - S57
  • [4] The course of neurocognitive functioning in high-grade glioma patients
    Bosma, Ingeborg
    Vos, Maaike J.
    Heimans, Jan J.
    Taphoorn, Martin J. B.
    Aaronson, Neil K.
    Postma, Tjeerd J.
    van der Ploeg, Henk M.
    Muller, Martin
    Vandertop, W. Peter
    Slotman, Ben. J.
    Klein, Martin
    [J]. NEURO-ONCOLOGY, 2007, 9 (01) : 53 - 62
  • [5] Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status
    Brandes, Alba A.
    Tosoni, Alicia
    Franceschi, Enrico
    Sotti, Guido
    Frezza, Giampiero
    Amista, Pietro
    Morandi, Luca
    Spagnolli, Federica
    Ermani, Mario
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1275 - 1279
  • [6] Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline
    Cabrera, Alvin R.
    Kirkpatrick, John P.
    Fiveash, John B.
    Shih, Helen A.
    Koay, Eugene J.
    Lutz, Stephen
    Petit, Joshua
    Chao, Samuel T.
    Brown, Paul D.
    Vogelbaum, Michael
    Reardon, David A.
    Chakravarti, Arnab
    Wen, Patrick Y.
    Chang, Eric
    [J]. PRACTICAL RADIATION ONCOLOGY, 2016, 6 (04) : 217 - 225
  • [7] Comparison of plan quality provided by intensity-modulated arc therapy and helical tomotherapy
    Cao, Daliang
    Holmes, Timothy W.
    Afghan, Muhammad K. N.
    Shepard, David M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (01): : 240 - 250
  • [8] Chan Maria F, 2003, Med Dosim, V28, P261, DOI 10.1016/j.meddos.2003.08.004
  • [9] Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma
    Chang, Eric L.
    Akyurek, Serap
    Avalos, Tedde
    Rebueno, Neal
    Spicer, Chris
    Garcia, John
    Famiglietti, Robin
    Allen, Pamela K.
    Chao, K. S. Clifford
    Mahajan, Anita
    Woo, Shiao Y.
    Maor, Moshe H.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (01): : 144 - 150
  • [10] RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
    Chinnaiyan, Prakash
    Won, Minhee
    Wen, Patrick Y.
    Rojiani, Amyn M.
    Wendland, Merideth
    Dipetrillo, Thomas A.
    Corn, Benjamin W.
    Mehta, Minesh P.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (05): : 880 - 884